Tafamidis for the Treatment of Transthyretin Amyloid Cardiomyopathy Tafamidis costs PACE organizations an estimated $240,000 per participant annually. This webinar will provide an overview of
An introduction to the CMS DMP requirements within the PACE model of care. Presented by CareKinesis and Pharmastar. For CareKinesis, Pharmastar, and CareVention clients –
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
MedWise® Science for Better Outcomes MedWise® Science is the heart of our medication optimization offerings. This software identifies potential multi-drug interactions in aggregate to help manage
CareKinesis is the first national PACE-centric, medication management and distribution pharmacy that focuses on reducing medication-related risk while enhancing economic, clinical, and humanistic outcomes.
©2021 Tabula Rasa HealthCare™
